Pharmacokinetics of anti-cancer drugs used in breast cancer chemotherapy.

@article{Nagar2010PharmacokineticsOA,
  title={Pharmacokinetics of anti-cancer drugs used in breast cancer chemotherapy.},
  author={Swati Nagar},
  journal={Advances in experimental medicine and biology},
  year={2010},
  volume={678},
  pages={
          124-32
        }
}
  • S. Nagar
  • Published 2010
  • Biology, Medicine, Chemistry
  • Advances in experimental medicine and biology
Pharmacokinetics of anticancer drugs used in breast cancer therapy are well established. This chapter reviews preclinical and clinical pharmacokinetics of the following drugs: cyclophosphamide, docetaxel, doxorubicin, 5-fluorouracil, methotrexate and tamoxifen. The absorption, distribution, metabolism and elimination of drugs are discussed in the context of breast cancer. The effect of age and menopause status on drug pharmacokinetics is evaluated. The important role of pharmacokinetic… 

Hormone-related pharmacokinetic variations associated with anti-breast cancer drugs

This review summarizes the pharmacokinetics of various types of drugs used to treat breast cancer and discusses hormone-related variations including: the menstrual status, gender and exogenous hormones influencing drug absorption, distribution, metabolism or excretion.

Pharmacokinetics and Pharmacogenetics of Metronomic Chemotherapy

Trials integrating pharmacokinetic and pharmacogenetics research are necessary to better evaluate the clinical benefit of metronomic chemotherapy.

Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors

The effectiveness of a combination of real-time reporters of TRAIL-induced apoptosis pathway in evaluating the efficacy of SC-TRAIL-based therapeutics is demonstrated and may have implications in targeting a broad range of cancers.

Nano Delivers Big: Designing Molecular Missiles for Cancer Therapeutics

This review addresses the rise of nanoparticle DDS platforms for cancer and explores concepts of gene/drug delivery and cytotoxicity in pre-clinical and clinical contexts.

Luteolin attenuates doxorubicin-induced cytotoxicity to MCF-7 human breast cancer cells.

The results suggest that a low concentration of luteolin attenuates doxorubicin-induced cytotoxicity to MCF-7 cells through a combination of antioxidant activity and an increase in levels of Bcl-2 protein.

Therapy-induced senescence drives bone loss.

The understanding of chemotherapy-induced bone loss is transformed by identifying senescent cells as major drivers of bone loss and the p38MAPK-MK2 axis as a putative therapeutic target that can preserve bone and improve a cancer survivor's quality of life.

insight of development and validation of bioanalytical method in the reference of anticancer drugs by using LC-MS/MS

The bioanalytical analysis of anticancer agents established a more personalized treatment procedure. The importance of validating analytical procedures before they are put into normal usage is widely

Chemotherapy-Induced Late Transgenerational Effects in Mice

To our knowledge, there is no report on long-term reproductive and developmental side effects in the offspring of mothers treated with a widely used chemotherapeutic drug such as doxorubicin (DXR),

Contribution of Organic Anion-Transporting Polypeptides 1A/1B to Doxorubicin Uptake and Clearance

Investigation of the role of organic anion transporting polypeptide (OATP) transporters to the disposition of doxorubicin demonstrates important roles for OATP1A/1B in transporter-mediated uptake and disposition ofDoxorUBicin.

References

SHOWING 1-10 OF 55 REFERENCES

Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer.

Docetaxel monotherapy has shown impressive activity as second-line therapy in patients with metastatic breast cancer who had relapsed while receiving adjuvant therapy or who had progressive disease following previous treatment, with overall response rates of 53 and 58% reported in 2 studies.

Clinical Pharmacokinetics of Docetaxel

Strategies to individualise docetaxel administration schedules based on phenotypic or genotype-dependent differences in CYP3A expression are underway and may ultimately lead to more selective chemotherapeutic use of this agent.

Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer.

It appears that a substantial part of 5-FU toxicity is not linked to pharmacokinetic factors and dose adjustments must still be on the basis of careful clinical surveillance.

Modulation of oral bioavailability of anticancer drugs: from mouse to man.

  • J. SchellensM. Malingré J. Beijnen
  • Biology, Medicine
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2000

Preclinical pharmacokinetics of paclitaxel and docetaxel.

Paclitaxel and docetaxel widely distribute into most tissues of mice and rats, including tumor tissue, but only low concentrations were detected in the central nervous system, and their metabolic profile is very distinct.

Effect of Exemestane on Tamoxifen Pharmacokinetics in Postmenopausal Women Treated for Breast Cancer

There is no pharmacokinetic interaction between tamoxifen and exemestane and no modification in the standard regimen of either drug seems to be indicated if they are used in combination.

Clinical Pharmacokinetics of Cyclophosphamide

Variations in the balance between metabolic activation and inactivation of cyclophosphamide owing to autoinduction, dose escalation, drug-drug interactions and individual differences have been reported, suggesting possibilities for optimisation of cyclphosphamide therapy.

Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.

  • J. IngleV. Suman M. Dowsett
  • Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1999
Estrogen suppression induced by letrozole was substantial despite the concomitant administration of TAM, and the antitumor effect of TAM plus letroZole was less than expected.
...